# A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

> **NCT06703021** · PHASE2 · COMPLETED · sponsor: **Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics** · enrollment: 85 (actual)

## Conditions studied

- Obesity
- Overweight
- Chronic Weight Management

## Interventions

- **DRUG:** aleniglipron or placebo
- **DRUG:** aleniglipron or placebo
- **DRUG:** aleniglipron or placebo
- **DRUG:** aleniglipron or placebo

## Key facts

- **NCT ID:** NCT06703021
- **Lead sponsor:** Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-20
- **Primary completion:** 2026-01-12
- **Final completion:** 2026-01-12
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703021, "A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06703021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*